Clinical Trial Update: Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323 [Phase 2]

View source ↗

Summary

A Phase 2 placebo-controlled study of CDP323 in relapsing forms of multiple sclerosis has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• CDP323

Snippet

Sponsor: UCB Pharma | Conditions: Multiple Sclerosis | Phase 2 | Status: TERMINATED